The FDA approved Moderna's new COVID-19 vaccine, mNexspike, which requires a lower dosage and targets high-risk populations aged 65 and above, as well as younger individuals with health conditions. This decision marks a significant shift in vaccination strategies, diverging from previous COVID-19 vaccine rollouts which were universally available. Moderna anticipates offering both the new vaccine and their existing one in the fall, while the approval follows the government's cancellation of funding for pandemic flu vaccine research, indicating changing priorities in public health response.
The new mNexspike vaccine by Moderna aims for lower doses and is designed to protect high-risk individuals, marking a shift in vaccine strategy.
Moderna's new COVID-19 vaccine is approved for specific age groups, mirroring limitations set by the FDA on competitor Novavax's vaccine.
Collection
[
|
...
]